Trials / Completed
CompletedNCT00468039
A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin
A Multicenter, Open-label Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin 100mg qd Plus Metformin 1000mg Bid in Drug Naive Patients With Type 2 Diabetes With Very Poor Glycemic Control
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 94 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 78 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the effects of treatment with vildagliptin and metformin as initial combination in newly diagnosed patients with type 2 diabetes who have very high levels of HbA1c and/or fasting plasma glucose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vildagliptin + metformin |
Timeline
- Start date
- 2007-03-06
- Primary completion
- 2008-06-06
- Completion
- 2008-06-06
- First posted
- 2007-05-01
- Last updated
- 2020-12-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00468039. Inclusion in this directory is not an endorsement.